rt-PA治疗急性缺血性卒中合并大脑中动脉高密度征的临床疗效观察

摘要

目的：：观察重组组织型纤溶酶原激活物(rt-PA)治疗急性缺血性卒中(CIS)合并大脑中动脉高密度征(HMCAS)的临床疗效。方法：107例CIS合并HMCAS的住院患者随机分为对照组(54例)和观察组(53例)。对照组予尿激酶治疗,观察组予rt-PA治疗,疗程均为14 d。治疗结束后评价两组患者的临床疗效与安全性。结果：与治疗前比较,两组患者各阶段NIHSS评分均明显降低,BI指数则明显升高(P<0.05)；且观察组两项指标均优于对照组(P<0.05)。观察组有效率为88.68%,高于对照组的79.63%(P<0.05)。结论：rt-PA静脉溶栓治疗CIS合并HMCAS患者疗效显著,并能改善患者生活质量,值得推广。%Objective:To observe the clinical efficacy of rt-PA in the treatment of patients with acute ischemic stroke ( CIS) and hyperdense middle cerebral artery sign ( HMCAS) . Methods:Totally 107 patients with CIS and HMCAS were randomly divided into the control group (n=54) and the treatment group (n=53). The control group was treated with urokinase, while the treatment group was treated with recombinant tissue type plasminogen activator ( rt-PA) . The treatment course was 14 days, and then the clinical effi-cacy and safety were evaluated. Results:Compared with that before the treatment, the score of national institute of health stroke scale ( NIHSS) in both groups was decreased after the treatment, and the decrease in the treatment group was more notable than that in the control group with statistically significant difference (P<0. 05). The clinical effective rate of the treatment group was 88. 68%, while that of the control group was 79. 63%, and there was statistically significant difference between the groups (P<0. 05). Compared with that before the treatment, BI index in both groups was increased after the treatment, and the increase in the treatment group was more significant than that in the control group with statistically significant difference (P<0. 05). Conclusion:rt-PA thrombolytic therapy in the patients with CIS and HMCAS has remarkable clinical efficacy, which can improve patients’ life quality and is worthy of promo-tion.